[ad_1]
As global vaccination accelerates the development of new Covid-19 models, pioneering scientists have worked to reduce the fear of another pandemic by developing a single shot to protect against past, present, and future coronaviruses.
Melanie Saville, head of vaccination and development research at the Coalition for Epidemic Preparedness Innovations, is one of the leaders in the project, calling for a vaccine that will significantly protect all betacoronaviruses and any other species “that can pass from animals to humans in the future. ”.
“[The] The way forward is close to two key questions, “he told the Financial Times.” What can we do to stop the epidemic and then what can we do to prevent the next epidemic? “
Sars-Cov-2, which has killed nearly 4m people in the last 18 months, is the third-largest betacoronavirus that has spread among humans over the past 20 years. The family of viruses, found in bats and rats, includes Sars-Cov-1, which killed more than 700 people in 2003, mainly in China and Hong Kong, and Mers-Cov, which was first identified in Saudi Arabia and in more than 850 people since 2012.
Since Covid-19 may not be the last coronavirus to transmit to humans, the development of a protective jab in both cases has become a major goal for some scientists. And as the Covid-19 continues to change faster than expected – with the recent rapid spread of the Delta, which first became known in India – interest in their work has increased.
In less than five years a “mass vaccine” that protects against several strains of disease “will have a very strong line against new strains,” Professor Chris Whitty, England’s chief medical officer, told UK staff this month.
But the path to a polyvalent or multivalent vaccine has many drawbacks. Researchers have been unsuccessful for decades in the search for HIV vaccine – a disease that often produces new strains – and the flu still needs to be changed every year.
Current Covid-19 vaccines, many of which have been very effective in combating Sars-Cov-2 and other subsequent strains, have focused on making antibodies to eliminate the protein used by the virus into human cells. . The problem with this method, Saville explained, could be that “the virus is mutated to prevent such an immune response… You need to update your vaccine more often”.
Many vaccines, in contrast, often fight off immune-promoting compounds, called epitopes, and attack mainly epitopes that are in a viral period that does not change, even when they are “in a state of flux,” according to Saville. Many of these shells also seek to promote the production of – including antibodies – T-cells, which, in turn, play a key role in the fight against the immune system in Covid-19.
Paul Higham, chief of Valo Therapeutics, said that by looking at epitopes with “significant changes,” his advanced vaccine was able to produce a T-cell solution that would work for Covid-19, Sars, Mers, and “Future Coronaviruses”. Higham hoped that the company from Helsinki and Oxford would have a vaccine ready for medical tests by the end of the year, adding that it would be available to the public “sometime in 2022”.
But developing a vaccine that can fight many germs is even more difficult. “Beyond that the viruses are based on their structure, depending on how they work, it is very difficult to find antibodies that can resist. [them], ”Explained Dennis Burton at the Scripps Research Institute in California, who has been running the HIV vaccine for years.
“For example, Sars-1 and Sars-2 are similar and we get a lot of antibodies that can fight both viruses.” But to add guns to help Mers, not to mention the future, various coronaviruses, was very difficult, he said.
Saville of CEPI believes that finding epitopes that can protect against various coronaviruses will require the use of artificial intelligence – one of the most widely used drug detection tools to accelerate research and development.
John Lewis, chief executive of Entos Pharmaceuticals, said his company had adopted a “machine learning method” because of its increased immunization. It teamed up with an expert AI company with a program that allows them to detect “34 different epithets from different coronavirus proteins” that can produce the most powerful human T-cell response.
“We are using fragments of protein that are more than 90% identical between Sars-1 and Sars-2 and are also found in another type of coronavirus where they appear to provide adequate protection,” he said. “They can’t defend completely but they have to defend a little bit on different teams.” Entos, based in Edmonton, Canada, hopes to launch a human test in the next two months.
OSE Immunotherapeutics, a French biotech company, has used an AI method that has already been developed for cancer vaccines. The technology allowed it to detect 12 epithets that target 11 proteins, most of which are infected, not on top of it. “Because they have the virus they don’t change or they don’t change at all,” explained Alexis Peyroles, a senior, adding that the same type of protein can be found in Sars-1 and Mers.
The jab people’s test begins with the expected results in September. OSE is already “preparing” phase 2, with financial support from the French bank, BPI France, and the third phase of 2022.
Peyroles said the vaccine could be especially effective for people with an immune system who have not developed a vaccine in response to an existing vaccine. But its widespread use can serve as a pan-coronavirus for everyone, easily adapted to new strains of the virus as it emerges. “If you had a base left over and added or removed new epitopes to a new coronavirus,” he said.
The VBI vaccine, based in Cambridge, Massachusetts, has taken a different approach. Like the latest Covid-19 vaccine, the VBI jab looks for a strong protein but has been able to respond to the whole body. “When we protect animals we make antibodies that can protect against Covid-19, Sars, and Mers – it’s like making antibodies that can detect red, yellow, and cloud,” says David Anderson, senior scientist.
“But the immune system changes and you can train it to see something that is a little bit between red and yellow, or yellow and cloudy, ‘spike proteins’. So now they see a shade of orange or green, which indicates that you have increased immunity. physically, “he said. “The goal is for these antibodies to be able to follow other strains that will continue to evolve over time.”
There is no initial “approach” to the company, but Anderson is optimistic. The gun has been funded by CEPI and the Canadian government as human trials are set to begin in the second half of this year.
VBI chief executive Jeff Baxter says he can have supervisors to discuss 12 to 14 months. “Science doesn’t always go as you expect, and it always changes as we learn more,” he said. “But it’s very exciting to think that maybe in just two years, everyone could be inspired by a more potent pan-coronavirus vaccine.”
[ad_2]
Source link
